Dyadic International (DYAI) investor relations material

Executive summary

• Transitioned from a development-stage platform to a commercial product-driven biotech with multiple revenue streams, including product launches and distribution agreements.

• Achieved commercial launch of AlbuFree DX recombinant human albumin, with profit-sharing from sales.

• Completed a corporate rebrand to Dyadic Applied BioSolutions and increased commercial efforts in Asia.

• Expanded collaborations and signed new agreements for animal-free proteins and enzymes across life sciences, food, and bio-industrial sectors.

• Focused on scaling product sales, advancing partner-led programs, and building recurring revenue through 2026 and beyond.

Financial highlights

• Total revenue for 2025 was $3.09 million, down from $3.5 million in 2024, mainly due to lower R&D collaboration and milestone revenue, partially offset by a $1.86 million increase in grant revenue.

• Net loss increased to $7.36 million ($0.23 per share) in 2025 from $5.81 million ($0.20 per share) in 2024.

• Loss from operations was $7.19 million in 2025, up from $5.90 million in 2024.

• Ended 2025 with $8.6 million in cash equivalents and investment-grade securities; net cash used in operations was $5.7 million.

• General and administrative expenses decreased to $5.76 million from $6.13 million; internal R&D expenses rose to $2.16 million from $2.04 million.

Outlook and guidance

• Expect disciplined cash usage in 2026, prioritizing high-impact R&D and grant-funded activities.

• Anticipate growth in product revenues in life sciences and food/nutrition, driven by new launches, with operating expenses in line with 2025.

• Current cash resources expected to provide runway into 2027; evaluating additional capital resources and partnerships.

• Focus remains on accelerating commercialization of animal-free proteins and enzymes and expanding product and channel offerings for long-term value.

• Anticipates broadening both partner-led and internal development programs in non-animal dairy proteins and enzymes.